Skeleton type roxithromycin sustained release pellet capsule

A technology of roxithromycin and sustained-release pellets, which is applied in the direction of medical preparations of non-active ingredients, organic active ingredients, oil/fat/wax non-effective ingredients, etc., and can solve the problem that the slow-release pellets cannot float and release Poor stability, long production process, etc., to achieve the effect of improving bioavailability, delaying release, and prolonging residence time
CN101224217BActive Publication Date: 2011-09-21西安远大德天药业股份有限公司
0 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
西安远大德天药业股份有限公司
Publication Date
2011-09-21

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The invention provides a matrix-typed roxithromycin sustained release micropill capsule which is prepared by 60-75wt percent of roxithromycin, 2-5wt percent of waxy matrix material, 10-25wt percent of microcrystalline cellulose, lactose, cane sugar or xylose, 2-5wt percent of hydrophilic matrix material, 1-4wt percent of anhydrous sodium carbonate and 4-10wt percent of mannite according to the normal preparation method. The waxy matrix material is octodecyl alcohol, cetyl alcohol, octadecanoic acid, glycerin monostearate or hydrogenated castor oil. The hydrophilic matrix material is xanthan gum, alginic acid or carbomer 974P. The matrix material adopted in the invention delays the release of the drug, reduces the density of sustained release micropill, prolongs the staying time of the sustained release micropill in the stomach and intestinal tract and improves the bioavailability of the medicine. A comparison test between the medicine of the invention and the roxithromycin sustained release pill is carried out in eighteen testers and the test shows that the matrix-typed roxithromycin slow-release micropill capsule of the invention and the roxithromycin slow-release pill have bioequiavailability.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of antibiotic drugs, and in particular relates to skeleton-type roxithromycin sustained-release pellet capsules. Background technique

[0002] Roxithromycin (RXM) is a semi-synthetic erythromycin derivative with a chemical name of 9-[0-[(2-methoxyethoxy)-methyl]oxime erythromycin. Roxithromycin is a new generation of 14-membered macrolide antibiotics. It was first used in France in 1988 and has been used in more than 90 countries in the world so far. Roxithromycin has good acid stability, is easy to absorb when taken orally, and has good pharmacokinetic characteristics. The antibacterial spectrum and antibacterial activity of roxithromycin in vitro are similar to erythromycin, and its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Very sensitive or moderately sensitive, it has moderate antibacteri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More